$0.01
-0.00(-18.67%)
Mkt Cap $5M
$0.01
$0.09
52-Week Range
At a Glance
AI-generatedAspire Biopharma's FY 2025 was defined by significant operating losses and cash burn as the company invested heavily in its development-stage operations, with minimal revenue generated from initial commercial activity.
Revenue breakdown: Nutraceutical Products (100%).
8-K
Aspire Biopharma Holdings, Inc. entered into a Securities Purchase Agreement for a private placement of Series A Convertible Preferred Stock, raising $11 million in gross proceeds at the initial closing and potentially up to $21 million in total. Concurrently, Donald G. Fell resigned from the Board and Philip Balatsos was appointed as a director.$5M
Market Cap
—
Revenue
—
Net Income
Employees2
Fundamentals
How The Business Makes Money
Revenue by Segment
Nutraceutical Products100%($6.2K)
Revenue by Geography
US99.2%($6.2K)
CA0.5%($30)
GB0.3%($19)
Activity
What Changed Recently
Company Profile
CIK0001847345
ISINUS7389201150
CUSIP738920115
Phone415 592 7399
Address23150 Fashion Drive, Estero, FL, 33928, US
SEC EDGAR